This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Lidocaine For Neuroprotection During Cardiac Surgery

This study is ongoing, but not recruiting participants.
National Heart, Lung, and Blood Institute (NHLBI)
CAS Medical Systems, Inc.
Information provided by (Responsible Party):
Duke University Identifier:
First received: July 10, 2009
Last updated: August 24, 2016
Last verified: August 2016
The purpose of this study is to see if a drug called lidocaine prevents cognitive injury (a decline in mental abilities) after heart surgery. Lidocaine is currently FDA approved and is commonly used for treating some heart rhythm disorders and for regional anesthesia (blocking nerves). The investigators are enrolling subjects in this research project to see if lidocaine will reduce the high incidence of cognitive injury seen after heart surgery. As part of this study, the investigators will also evaluate the relationship between cognitive injury and genetic makeup and the chemical changes in the subjects blood during and after surgery.

Condition Intervention
Cognitive Decline Drug: Lidocaine Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Lidocaine For Neuroprotection During Cardiac Surgery

Resource links provided by NLM:

Further study details as provided by Duke University:

Primary Outcome Measures:
  • Change in cognitive function from baseline [ Time Frame: 6 weeks after surgery ]

Secondary Outcome Measures:
  • Platelet and white blood cell activation gradients [ Time Frame: Intraoperative ]
  • Change in quality of Life, as measured by questionnaires [ Time Frame: baseline, 6-weeks, and 1-year ]
  • Change in neurological function, as measured by neurological assessment scores [ Time Frame: baseline, 6-weeks, and 1-year ]
  • Change in cognitive function from baseline [ Time Frame: 1 year after surgery ]

Estimated Enrollment: 476
Study Start Date: July 2009
Estimated Study Completion Date: July 2017
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lidocaine
Lidocaine infusion for 48 hours
Drug: Lidocaine
Lidocaine versus placebo infusion for 48 hours
Placebo Comparator: Placebo
Normal saline infusion for 48 hours
Drug: Placebo
Lidocaine versus placebo infusion for 48 hours


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. CABG, CABG + Valve, or Valve surgery
  2. Use of cardiopulmonary bypass

Exclusion Criteria:

  1. Less than 50 years of age
  2. History of diabetes
  3. History of symptomatic cerebrovascular disease (e.g. prior stroke) with residual deficit
  4. Alcoholism (> 2 drinks/day)
  5. History of psychiatric illness (any clinical diagnoses requiring therapy)
  6. History of drug abuse (any illicit drug use in the past 3 months)
  7. Hepatic insufficiency (liver function tests > 1.5 times the upper limit of normal)
  8. Severe pulmonary insufficiency (requiring home oxygen therapy)
  9. Renal failure (baseline serum creatinine > 2.0 mg/dl)
  10. Pregnant women
  11. Unable to read and thus unable to complete the cognitive testing
  12. Score < 24 on a baseline Mini Mental State examination (MMSE) or greater than or equal to 27 on the baseline Center for Epidemiological Studies Depression (CES-D) Scale -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00938964

United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Virginia
Sentara Cardiovascular Research Institute
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Duke University
National Heart, Lung, and Blood Institute (NHLBI)
CAS Medical Systems, Inc.
Principal Investigator: Joseph P Mathew, M. D. Duke University
  More Information

Rey A. L'examen clinique en psychologie. Paper presented at : Presses Universitaires de France, 1964; Paris
Randt C, Brown E. Administration Manual: Randt Memory Test. New Youk Life Sciences Associates; 1983
Wechsler D. The Wechsler Adult Intelligence Sacle-Revised (Manual): Psychological Corporation: 1981.
Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills, 1958; 8:271-276
Mark DB, Nelson C, Delong E, et al. Comparisin of quality of life outcomes following coronary angioplasty, coronary bypass surgery and medicine. J Am Coll Cardiol. 1993; 21:216A
McDowell I, Newell C. Measuring Health: A Guide To Rating Scales And Questionnaires. New York: Oxford University Press; 1987.
Cronbach LJ. Essentials of Psycological Testing. New York: Harper and Row; 1970
Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Statist Soc B. 1995;57(1):289-300

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Duke University Identifier: NCT00938964     History of Changes
Other Study ID Numbers: Pro00015641
R01HL096978 ( U.S. NIH Grant/Contract )
Study First Received: July 10, 2009
Last Updated: August 24, 2016

Keywords provided by Duke University:

Additional relevant MeSH terms:
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action processed this record on August 21, 2017